Rishi Gupta - May 11, 2023 Form 4 Insider Report for Verona Pharma plc (VRNA)

Role
Director
Signature
/s/ Rishi Gupta
Stock symbol
VRNA
Transactions as of
May 11, 2023
Transactions value $
-$9,938,132
Form type
4
Date filed
5/15/2023, 06:06 PM
Previous filing
Apr 28, 2023
Next filing
May 19, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRNA Ordinary Shares Sale -$1.78M -80K -1.88% $22.26 4.18M May 11, 2023 See footnotes F1, F2, F3
transaction VRNA Ordinary Shares Sale -$935K -43.2K -1.03% $21.64 4.14M May 12, 2023 See footnotes F1, F2, F3
transaction VRNA Ordinary Shares Sale -$316K -14.4K -0.35% $21.96 4.12M May 15, 2023 See footnotes F1, F2, F3
transaction VRNA Ordinary Shares Sale -$6.91M -345K -8.38% $20.00 3.78M May 15, 2023 See footnotes F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of American Depository Shares ("ADSs") held of record by OrbiMed Private Investments VI, LP ("OPI VI"). Each ADS represents eight Ordinary Shares of the Issuer.
F2 These securities are held of record by OPI VI. OrbiMed Capital GP VI LLC ("OrbiMed GP") is the general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of OrbiMed GP. By virtue of such relationships, OrbiMed GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI.
F3 Each of the Reporting Person, OrbiMed Advisors, and OrbiMed GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.